Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

In midst of Epipen shortage, Kaleo confirms ‘sufficient supply’ of Auvi-Q auto-injectors

August 14, 2018 By Sarah Faulkner

Kaleo

Kaleo said today that despite ongoing manufacturing delays reported by epinephrine auto-injector manufacturers, Kaleo’s Auvi-Q device is available via prescription and that the privately-held company has ‘sufficient supply to meet any anticipated demand.’ Kaleo’s epinephrine auto-injector features voice instructions that guide users through the drug-delivery process and an auto-retractable needle system, according to the company. […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Hospira Inc., Impax Laboratories, Kaleo Inc, Mylan

Impax settles ‘fax-blasting’ class action suit over EpiPen alternative

September 7, 2017 By Sarah Faulkner

Impax Laboratories

Impax Laboratories (NSDQ:IPXL) will pony up $4.8 million to settle claims that it sent blasts of unsolicited faxes to Family Medicine Pharmacy advertising its epinephrine auto-injector, according to a document filed in a Alabama federal court this week. The Alabama-based pharmacy filed the proposed class action suit against Impax in January, alleging that the pharmaceutical company […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Impax Laboratories, Kaleo Inc, Mylan

Express Scripts covers Mylan’s EpiPen on 2018 formulary, excluding rivals

August 1, 2017 By Sarah Faulkner

EpiPen

Express Scripts (NSDQ:ESRX) said yesterday that it would include Mylan‘s (NSDQ:MYL) EpiPen emergency allergy device on its 2018 formulary, favoring the drugmaker’s product over auto-injectors from competitors like Impax Laboratories (NSDQ:IPXL)  and Kaleo. The largest pharmacy benefit manager in the U.S. has practiced excluding certain medicines from its list of covered drugs since 2014, pointing towards […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Express Scripts, Impax Laboratories, Kaleo Inc, Mylan

Adamis up, Mylan down on generic EpiPen approval

June 16, 2017 By Sarah Faulkner

Adamis Pharmaceuticals

Shares in Adamis Pharmaceuticals (NSDQ:ADMP) soared more than 50% yesterday after it won FDA approval for its generic EpiPen emergency allergy pre-filled syringe, sending shares in competitor Mylan (NSDQ:MYL) down -3%. For years, Mylan has commanded more than 90% of the market for emergency epinephrine injectors. Adamis’ device, called Symjepi, is intended to be a cheaper […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: adamispharmaceuticals, Impax Laboratories, Mylan

Impax shares climb despite Q1 miss

May 12, 2017 By Sarah Faulkner

Impax Laboratories

Shares in Impax Laboratories (NSDQ:IPXL) rose earlier this week even though the pharmaceutical company missed expectations on Wall Street with its Q1 results. The Hayward, Calif.-based company posted profits of $7.7 million on sales of $184.4 million for the 3 months ended March 31, for bottom-line loss of -75% on sales loss of -18.2% compared with the same […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Impax Laboratories

Demand for EpiPen alternatives jumps as states consider access legislation

March 7, 2017 By Sarah Faulkner

Mylan

Prescriptions for EpiPen alternatives such as Kaléo Inc.‘s Auvi-Q device have quadrupled since the beginning of this year, according to data from the Athenahealth Network. The demand for cheaper alternative devices is likely driven by revelations that Mylan (NSDQ:MYL) hiked the price of its EpiPen emergency allergy injector by 500% since it acquired the device in 2007. Generic […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Respiratory, Wall Street Beat Tagged With: Impax Laboratories, Kaleo Inc, Mylan, Teva Pharmaceuticals

CVS to sell cheaper, generic version of Impax’s allergy injection

January 12, 2017 By Sarah Faulkner

Impax Laboratories

CVS Health Corp. (NYSE:CVS) said today that it will start selling a generic version of Impax Laboratories‘ (NSDQ:IPXL) emergency allergy injection, Adrenaclick. The device is similar to Mylan‘s (NSDQ:MYL) EpiPen, although regulators do not consider the 2 devices to be exactly the same. The Adrenaclick has a list price of more than $400, but the generic […]

Filed Under: Drug-Device Combinations, Featured, Respiratory, Wall Street Beat Tagged With: CVS Health, Impax Laboratories, Mylan

Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS